Mitochondrial Myopathies Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight
Mitochondrial Myopathies Companies are Stealth BioTherapeutics, Reneo Pharmaceuticals, Abliva AB, Omeicos Therapeutics, Khondrion BV, Tisento Therapeutics, UCB BIOSCIENCES, Inc., and others.
(Albany, USA) DelveInsight's ' Mitochondrial Myopathies Market Insights, Epidemiology, and Market Forecast-2032 ″ report offers an in-depth understanding of the Mitochondrial Myopathies, historical and forecasted epidemiology as well as the Mitochondrial Myopathies market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Mitochondrial Myopathies market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Mitochondrial Myopathies market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Mitochondrial Myopathies treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Mitochondrial Myopathies market.
To Know in detail about the Mitochondrial Myopathies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mitochondrial Myopathies Market Forecast
Some of the key facts of the Mitochondrial Myopathies Market Report:
· The Mitochondrial Myopathies market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
· In December 2023, Reneo Pharmaceuticals, based in the US, intends to implement cost-cutting measures, including reducing its workforce by 70%, following the Phase III trial failure of its leading candidate mavodelpar. The Phase III STRIDE trial (NCT04535609) assessed mavodelpar in adult patients with primary mitochondrial myopathies (PMM). Unfortunately, the drug did not show a significant improvement in the distance walked during the 12-minute walk test (12MWT) at week 24, which was the primary endpoint of the study.
· In Septemer 2023, Stealth BioTherapeutics Inc., a biotechnology company advancing treatments for diseases linked to mitochondrial dysfunction, has announced the completion of target enrollment in the NuPOWER (SPIMD-301) study for patients with primary mitochondrial myopathy (PMM). The study will continue enrolling participants through the end of the month to accommodate additional interested patients.
· According to Bottoni et al. (2023), the estimated prevalence of mitochondrial diseases in children ranges from 4.7 to 15 per 100,000.
· According to research conducted by Ibayashi et al. (2023) in Japan, there were 3,629 patients diagnosed with mitochondrial diseases, with a prevalence of 2.9 per 100,000 in the general population. The distribution of females to males was 53 to 47, and the most common age group affected was between 40 and 49 years old.
· According to the American Academy of Ophthalmology (2023), up to 60% of cases of mitochondrial chronic progressive external ophthalmoplegia (CPEO) are attributed to deletions in mitochondrial DNA (mtDNA). Other cases result from defects in nuclear DNA (nDNA) affecting mtDNA maintenance, such as mutations in genes like POLG1, ANT, C10orf2/twinkle, or POLG2. Sporadic cases of CPEO are linked to new mutations in mtDNA, while autosomal dominant or recessive inheritance patterns suggest mutations in nuclear DNA.
· Key Mitochondrial Myopathies Companies: Stealth BioTherapeutics, Reneo Pharmaceuticals, Abliva AB, Omeicos Therapeutics, Khondrion BV, Tisento Therapeutics, UCB BIOSCIENCES, Inc., and others
· Key Mitochondrial Myopathies Therapies: Elamipretide, REN001, KL1333, OMT-28, Sonlicromanol, zagociguat, doxecitine and doxribtimine, and others
· The Mitochondrial Myopathies market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mitochondrial Myopathies pipeline products will significantly revolutionize the Mitochondrial Myopathies market dynamics.
Mitochondrial Myopathies Overview
Mitochondrial Myopathies are a group of neuromuscular diseases caused by defects in mitochondria—the energy-producing components of cells. Mitochondrial Myopathies symptoms can vary widely but often include muscle weakness, exercise intolerance, neurological issues, and fatigue. Mitochondrial Myopathies causes stem from genetic mutations, either inherited from the mother or arising spontaneously. Mitochondrial Myopathies diagnosis involves clinical evaluation, muscle biopsy, genetic testing, and biochemical analysis.
Mitochondrial Myopathies treatment is largely supportive, focusing on managing symptoms and slowing progression. While there is no definitive cure, Mitochondrial Myopathies management may include physical therapy, vitamin and coenzyme supplementation, and specialized dietary approaches. Mitochondrial Myopathies in children may present differently than in adults, often with more severe manifestations.
Mitochondrial Myopathies research is ongoing to discover targeted therapies and improve quality of life. Mitochondrial Myopathies prognosis varies depending on the specific mutation and severity of symptoms. Mitochondrial Myopathies awareness is growing among healthcare providers, leading to earlier detection and intervention.
Mitochondrial Myopathies support groups and advocacy organizations play a key role in patient education and research funding. Mitochondrial Myopathies specialists such as neurologists and geneticists are crucial for accurate diagnosis and care planning.
Mitochondrial Myopathies require a multidisciplinary approach to optimize patient outcomes.
Mitochondrial Myopathies Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Mitochondrial Myopathies Epidemiology Segmentation:
The Mitochondrial Myopathies market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
· Total Prevalence of Mitochondrial Myopathies
· Prevalent Cases of Mitochondrial Myopathies by severity
· Gender-specific Prevalence of Mitochondrial Myopathies
· Diagnosed Cases of Episodic and Chronic Mitochondrial Myopathies
Download the report to understand which factors are driving Mitochondrial Myopathies epidemiology trends @ Mitochondrial Myopathies Epidemiology Forecast
Mitochondrial Myopathies Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mitochondrial Myopathies market or expected to get launched during the study period. The analysis covers Mitochondrial Myopathies market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Mitochondrial Myopathies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
The market for mitochondrial myopathies is influenced by several drivers and barriers. On the driving side, increased awareness and understanding of mitochondrial disorders have led to earlier diagnoses, expanding the patient pool seeking treatments. Advancements in genetic research and biotechnology have spurred the development of novel therapeutic approaches, attracting investment from pharmaceutical companies. Additionally, government initiatives and funding for rare diseases have provided financial support for research and development in this area. However, the market faces significant barriers, including the complexity of mitochondrial diseases, which complicates the development of effective treatments. The high costs associated with research and clinical trials for rare diseases can deter investment, and the small patient population limits potential revenue, making it less attractive for some companies. Furthermore, regulatory challenges specific to rare diseases can delay the approval and commercialization of new therapies. Balancing these drivers and barriers is crucial for stakeholders aiming to advance the mitochondrial myopathies market.
Mitochondrial Myopathies Therapies and Key Companies
· Elamipretide: Stealth BioTherapeutics
· REN001: Reneo Pharmaceuticals
· KL1333: Abliva AB
· OMT-28: Omeicos Therapeutics
· KL1333: Abliva AB
· Sonlicromanol: Khondrion BV
· zagociguat: Tisento Therapeutics
· doxecitine and doxribtimine: UCB BIOSCIENCES, Inc.
Mitochondrial Myopathies Market Strengths
· Growing recognition of mitochondrial myopathies among healthcare professionals and the general public is leading to improved diagnosis rates and access to care
· Ongoing research into mitochondrial function and disease mechanisms is leading to potential breakthroughs in treatment options and management strategies
Mitochondrial Myopathies Market Opportunities
Continued research into mitochondrial function and disease mechanisms may lead to the development of targeted therapies aimed at restoring mitochondrial function or mitigating disease progression
Scope of the Mitochondrial Myopathies Market Report
· Study Period: 2019–2032
· Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
· Key Mitochondrial Myopathies Companies: Stealth BioTherapeutics (NASDAQ: MITO), Reneo Pharmaceuticals (NASDAQ: RPHM), Abliva AB (STO: ABLI), Omeicos Therapeutics (Private), Khondrion BV (Private), Tisento Therapeutics (Private), UCB BIOSCIENCES, Inc. (EBR: UCB), and others.
· Key Mitochondrial Myopathies Therapies: Elamipretide, REN001, KL1333, OMT-28, Sonlicromanol, zagociguat, doxecitine and doxribtimine, and others
· Mitochondrial Myopathies Therapeutic Assessment: Mitochondrial Myopathies current marketed and Mitochondrial Myopathies emerging therapies
· Mitochondrial Myopathies Market Dynamics: Mitochondrial Myopathies market drivers and Mitochondrial Myopathies market barriers
· Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
· Mitochondrial Myopathies Unmet Needs, KOL's views, Analyst's views, Mitochondrial Myopathies Market Access and Reimbursement
To know more about Mitochondrial Myopathies companies working in the treatment market, visit @ Mitochondrial Myopathies Clinical Trials and Therapeutic Assessment
Table of Contents
1. Mitochondrial Myopathies Market Report Introduction
2. Executive Summary for Mitochondrial Myopathies
3. SWOT analysis of Mitochondrial Myopathies
4. Mitochondrial Myopathies Patient Share (%) Overview at a Glance
5. Mitochondrial Myopathies Market Overview at a Glance
6. Mitochondrial Myopathies Disease Background and Overview
7. Mitochondrial Myopathies Epidemiology and Patient Population
8. Country-Specific Patient Population of Mitochondrial Myopathies
9. Mitochondrial Myopathies Current Treatment and Medical Practices
10. Mitochondrial Myopathies Unmet Needs
11. Mitochondrial Myopathies Emerging Therapies
12. Mitochondrial Myopathies Market Outlook
13. Country-Wise Mitochondrial Myopathies Market Analysis (2019–2032)
14. Mitochondrial Myopathies Market Access and Reimbursement of Therapies
15. Mitochondrial Myopathies Market Drivers
16. Mitochondrial Myopathies Market Barriers
17. Mitochondrial Myopathies Appendix
18. Mitochondrial Myopathies Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BreakingNews.ie
3 minutes ago
- BreakingNews.ie
Government at risk of normalising rising homlesssness, says Sinn Féin TD
Sinn Féin housing spokesperson Eoin Ó Broin says the Government are at risk of normalising rising numbers of homelessness. Mr Ó Broin made the comments as it was confirmed that homeless figures have once again risen to record levels, with 15,747 people now in emergency accommodation. Advertisement Of those people, 4,844 children were accessing emergency accommodation during the last week of May. Speaking to , Mr Ó Broin pointed out that the number of homeless people has increased every month under the current Government. "Every month since this Government has been in office, the numbers have increased. "The latest figures for May show increases across every level of homelessness. Adult homelessness, child homelessness, singles, children, families, and pensioners. Advertisement "The constant rise in child homelessness is deeply concerning, and a direct result of Government failure. "The policies they are pursuing are failing, and in particular, they are failing children. What we need is a radical change in direction. Without that, my concern is we will continue to see record highs every month. "They are in denial about the scale of the emergency we are in. They are in denial of how their policies have caused this crisis, and they are spending far too much time blaming everybody else, for an emergency of their making." The Sinn Féin TD says the Government are now at risk of normalising homelessness, and is not taking into account the effect homelessness has on people. Advertisement "I think the Government is at risk of normalising ever rising levels of homelessness, but also the enormous impact of staying in emergency accommodation has on adults, and particularly children. "Every time I hear a Government minister or the Taoiseach say housing the homeless is the number one priority, the problem is you can't keep saying that when month on month, your actions and inactions are leading to an ever greater number of people being homeless. "Ultimately, the solution to this is accelerating the delivery of social and affordable homes, and also the kind of homes in the right place." Mr Ó Broin also voiced his concern over changes to the Rent Pressure Zones which were recently confirmed by the Government. Advertisement New tenancies created from March 1st, 2026 onwards will be set at market value and offer six-year minimum rolling tenancies. At the end of the six-year tenancy, the rent can be reset and 'put back to the market', meaning the first series of rent resets under the reforms will take place in 2032. Mr Ó Broin says he fears rents will increase to a point which people will not be able to afford under the new changes. "One of the big concerns about the Rent Pressure Zones from March next year, when the rules come in, we are going to see over a period of time, rents right across the private rental sector reset to market rents, and that is something renters will not be able to afford. "It is important to remember the reason rent regulations were introduced in the first place in 2016 is because rents in the private rental sector were increasing 20 per cent plus a year. "Families were unable to afford those rents, falling into rental arrears and then emergency accommodation. "The idea that dismantling that is the solution, is utter madness."
Mint
4 minutes ago
- Mint
India makes strides on UN development goals, but challenges persist
New Delhi: India has made measurable progress across several of the 17 UN Sustainable Development Goals (SDGs), but persistent gaps in critical segments continue to challenge its development trajectory, the government's latest progress report shows. The SDG National Indicator Framework Progress Report 2025, released by the ministry of statistics and programme implementation (MoSPI) on Sunday to mark the 19th Statistics Day, presents a detailed time-series assessment of over 280 national indicators aligned with all 17 SDG goals. The 17 SDGs, agreed to by all governments in 2015, are non-binding policy objectives for sustainable development, and include targets such as removing poverty and hunger, and ensuring good health, quality education, and gender equality by 2030. Among the standout gains, budgetary allocation to the department of health research soared by over 400% between FY16 and FY26. Institutional credit to agriculture rose from 0.76 times the value of agricultural output in FY16 to 1.56 times by FY24, signalling stronger financial backing for the farm sector. Food security coverage also expanded, with a rising share of beneficiaries under the National Food Security Act, 2013 between FY16 and FY25. Access to basic services showed marked improvement. The SDG National Indicator Framework Progress Report 2025 serves as a valuable tool for policymakers to identify priority areas requiring interventions, Rao Inderjit Singh, minister of state (independent charge) of MoSPI, said in a statement. "This year holds special significance as it marks a decade since the adoption of the SDGs in 2015," he said. "This milestone offers a moment for both reflection and renewed commitment—an opportunity to evaluate our progress and recalibrate our path toward achieving the Agenda 2030," he added. The proportion of households with toilets, electricity, clean cooking fuel, and piped drinking water rose significantly over the past decade. The share of renewable energy in total installed power capacity also grew between FY20 and FY25. Yet, the report highlights several areas of concern. Government expenditure on essential services, education, health, and social protection edged down slightly from FY16 to FY24. The issuance of soil health cards to farmers declined from full coverage between 2015 and 2017 to 87.25% in FY25. The net sown area as a share of cultivable land dipped, while road accident fatalities rose from 11.81 per 1,00,000 population in 2015 to 12.4 in 2022. Alarmingly, the adolescent birth rate in girls aged 15–19 increased slightly from 11.1 per 1,000 in 2015 to 11.3 in 2021. Cases of dowry-related offences and overall crimes against women also trended upward between 2015 and 2022. On the economic front, India's FY25 GDP is projected to grow at 6.5%, just shy of the 7% annual target set under SDG 8. However, the manufacturing sector's annual growth rate has moderated since FY16. Built on data provided by various ministries and departments, the report offers a comprehensive snapshot of India's SDG trajectory, showcasing progress where policy interventions have worked, while flagging critical gaps that demand urgent, targeted action. Meanwhile, Saurabh Garg, secretary at MoSPI, said that the year 2025 is a pivotal midpoint in the SDG journey, underscoring the need to assess progress and refine strategies to stay on course for the 2030 targets. "It (the report) serves not only as a tool for monitoring progress on SDGs but also as a reference for identifying challenges and recommending follow-up actions at the national level," he added.
eNCA
4 minutes ago
- eNCA
Morocco's Atlantic gambit: linking restive Sahel to ocean
A planned trade corridor linking the landlocked Sahel to the Atlantic is at the heart of an ambitious Moroccan project to tackle regional instability and consolidate its grip on disputed Western Sahara. The "Atlantic Initiative" promises ocean access to Mali, Burkina Faso and Niger through a new $1.3-billion port in the former Spanish colony claimed by the pro-independence Polisario Front but largely controlled by Morocco. But the project remains fraught with challenges at a time when military coups in the Sahel states have brought new leaderships to power intent on overturning longstanding political alignments following years of jihadist violence. The Moroccan initiative aims to "substantially transform the economy of these countries" and "the region", said King Mohammed VI when announcing it in late 2023. The "Dakhla Atlantic" port, scheduled for completion at El Argoub by 2028, also serves Rabat's goal of cementing its grip on Western Sahara after US President Donald Trump recognised its sovereignty over the territory in 2020. Morocco's regional rival Algeria backs the Polisario but has seen its relations with Mali, Burkina Faso and Niger fray in recent months after the downing a Malian drone. Military coups over the past five years have seen the three Sahel states pivot towards Russia in a bid to restore their sovereignty and control over natural resources after decades within the sphere of influence of their former colonial ruler France. French troops were forced to abandon their bases in the three countries, ending their role in the fight against jihadists who have found sanctuary in the vast semi-arid region on the southern edge of the Sahara. - 'Godsend' - AFP | Abdel Majid BZIOUAT After both the African Union and West African bloc ECOWAS imposed economic sanctions on the new juntas, Morocco emerged as an early ally, with Niger calling the megaproject "a godsend". "Morocco was one of the first countries where we found understanding at a time when ECOWAS and other countries were on the verge of waging war against us," Niger's Foreign Minister Bakary Yaou Sangare said in April during a visit to Rabat alongside his Malian and Burkinabe counterparts. The Sahel countries established a bloc of their own -- the Alliance of Sahel States (AES) -- in September 2023 but have remained dependent on the ports of ECOWAS countries like Benin, Ghana, Ivory Coast and Togo. Rising tensions with the West African bloc could restrict their access to those ports, boosting the appeal of the alternative trade outlet being offered by Rabat. - 'Many steps to take' - AFP | Abdel Majid BZIOUAT Morocco has been seeking to position itself as a middleman between Europe and the Sahel states, said Beatriz Mesa, a professor at the International University of Rabat. With jihadist networks like Al-Qaeda and the Islamic State group striking ever deeper into sub-Saharan Africa, the security threat has intensified since the departure of French-led troops. Morocco was now "profiting from these failures by placing itself as a reliable Global South partner", Mesa said. Its initiative has won the backing of key actors including the United States, France and the Gulf Arab states, who could provide financial support, according to specialist journal Afrique(s) en mouvement. But for now the proposed trade corridor is little more than an aspiration, with thousands of kilometres of desert road-building needed to turn it into a reality. "There are still many steps to take," since a road and rail network "doesn't exist", said Seidik Abba, head of the Sahel-focused think tank CIRES. Rida Lyammouri of the Policy Center for the New South said the road route from Morocco through Western Sahara to Mauritania is "almost complete", even though it has been targeted by Polisario fighters. Abdelmalek Alaoui, head of the Moroccan Institute for Strategic Intelligence, said it could cost as much as $1 billion to build a land corridor through Mauritania, Mali and Niger all the way to Chad, 3,100 kilometres to the east. And even if the construction work is completed, insecurity is likely to pose a persistent threat to the corridor's viability, he said. By Anouk Riondet
